Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.30), $0.19 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $164.9 million versus the consensus estimate of $183.28 million.

GUIDANCE:

Corcept Therapeutics sees FY2026 revenue of $0.95-1.05 billion, versus the consensus of $0.93 billion.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.